Evan Seigerman
Stock Analyst at BMO Capital
(4.12)
# 484
Out of 5,140 analysts
154
Total ratings
55.88%
Success rate
11.96%
Average return
Main Sectors:
Stocks Rated by Evan Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $147 → $140 | $128.63 | +8.84% | 16 | Feb 12, 2026 | |
| BIIB Biogen | Maintains: Market Perform | $165 → $196 | $192.03 | +2.07% | 28 | Feb 9, 2026 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $35 → $54 | $39.23 | +37.65% | 3 | Dec 9, 2025 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $1,100 → $1,200 | $1,009.52 | +18.87% | 10 | Dec 4, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $120 → $130 | $151.40 | -14.13% | 18 | Aug 8, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $557 → $530 | $476.90 | +11.13% | 16 | Aug 5, 2025 | |
| INCY Incyte | Maintains: Underperform | $52 → $60 | $101.32 | -40.78% | 13 | Jul 30, 2025 | |
| IRON Disc Medicine | Maintains: Outperform | $112 → $120 | $61.36 | +95.57% | 6 | May 12, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Market Perform | $57 → $61 | $60.66 | +0.56% | 11 | Nov 12, 2024 | |
| GPCR Structure Therapeutics | Initiates: Outperform | $40 | $66.55 | -39.89% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $40 | $8.64 | +362.96% | 1 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $757 → $788 | $779.67 | +1.07% | 17 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $8 → $2.5 | $5.44 | -54.04% | 2 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $263 → $243 | $374.75 | -35.16% | 6 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $5.11 | +135.06% | 2 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $26.65 | +125.14% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $30 | $1.71 | +1,659.53% | 3 | May 12, 2020 |
Neurocrine Biosciences
Feb 12, 2026
Maintains: Market Perform
Price Target: $147 → $140
Current: $128.63
Upside: +8.84%
Biogen
Feb 9, 2026
Maintains: Market Perform
Price Target: $165 → $196
Current: $192.03
Upside: +2.07%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $35 → $54
Current: $39.23
Upside: +37.65%
Eli Lilly and Company
Dec 4, 2025
Maintains: Outperform
Price Target: $1,100 → $1,200
Current: $1,009.52
Upside: +18.87%
Gilead Sciences
Aug 8, 2025
Maintains: Outperform
Price Target: $120 → $130
Current: $151.40
Upside: -14.13%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Outperform
Price Target: $557 → $530
Current: $476.90
Upside: +11.13%
Incyte
Jul 30, 2025
Maintains: Underperform
Price Target: $52 → $60
Current: $101.32
Upside: -40.78%
Disc Medicine
May 12, 2025
Maintains: Outperform
Price Target: $112 → $120
Current: $61.36
Upside: +95.57%
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Market Perform
Price Target: $57 → $61
Current: $60.66
Upside: +0.56%
Structure Therapeutics
Feb 28, 2023
Initiates: Outperform
Price Target: $40
Current: $66.55
Upside: -39.89%
Oct 14, 2022
Maintains: Outperform
Price Target: $30 → $40
Current: $8.64
Upside: +362.96%
Aug 4, 2022
Maintains: Outperform
Price Target: $757 → $788
Current: $779.67
Upside: +1.07%
Aug 2, 2022
Downgrades: Market Perform
Price Target: $8 → $2.5
Current: $5.44
Upside: -54.04%
Apr 28, 2022
Maintains: Market Perform
Price Target: $263 → $243
Current: $374.75
Upside: -35.16%
Mar 31, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $5.11
Upside: +135.06%
Nov 19, 2021
Initiates: Outperform
Price Target: $60
Current: $26.65
Upside: +125.14%
May 12, 2020
Maintains: Outperform
Price Target: $13 → $30
Current: $1.71
Upside: +1,659.53%